Irradiation and anti–PD-L1 treatment synergistically promote antitumor …

Articles citing Irradiation and anti–PD-L1 treatment synergistically promote antitumor …

Title / Author	Year
Immune checkpoint blockade in cancer therapy MA Postow, MK Callahan, JD Wolchok Journal of clinical oncology 33 (17), 1974	2015
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929	2017
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations W Zou, JD Wolchok, L Chen Science translational medicine 8 (328), 328rv4-328rv4	2016
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence HE Barker, JTE Paget, AA Khan, KJ Harrington Nature reviews Cancer 15 (7), 409	2015
STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors L Deng, H Liang, M Xu, X Yang, B Burnette, A Arina, XD Li, H Mauceri, ... Immunity 41 (5), 843-852	2014
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade SJ Dovedi, AL Adlard, G Lipowska-Bhalla, C McKenna, S Jones, ... Cancer research 74 (19), 5458-5468	2014
Neutrophils in cancer: neutral no more SB Coffelt, MD Wellenstein, KE de Visser Nature Reviews Cancer 16 (7), 431	2016
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway KC Ohaegbulam, A Assal, E Lazar-Molnar, Y Yao, X Zang Trends in molecular medicine 21 (1), 24-33	2015
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant K Reynders, T Illidge, S Siva, JY Chang, D De Ruysscher Cancer treatment reviews 41 (6), 503-510	2015
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy AB Sharabi, M Lim, TL DeWeese, CG Drake The lancet oncology 16 (13), e498-e509	2015
Stereotactic radiation therapy augments antigen-specific PD-1–mediated antitumor immune responses via cross-presentation of tumor antigen AB Sharabi, CJ Nirschl, CM Kochel, TR Nirschl, BJ Francica, E Velarde, ... Cancer immunology research 3 (4), 345-355	2015
Coinhibitory pathways in immunotherapy for cancer SH Baumeister, GJ Freeman, G Dranoff, AH Sharpe Annual review of immunology 34, 539-573	2016
Role of local radiation therapy in cancer immunotherapy S Demaria, EB Golden, SC Formenti JAMA oncology 1 (9), 1325-1332	2015
Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer J He, Y Hu, M Hu, B Li Scientific reports 5, 13110	2015
PD-L1 expression in human cancers and its association with clinical outcomes X Wang, F Teng, L Kong, J Yu OncoTargets and therapy 9, 5023	2016
Current clinical trials testing the combination of immunotherapy with radiotherapy J Kang, S Demaria, S Formenti Journal for immunotherapy of cancer 4 (1), 51	2016
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350	2018
Radiotherapy and immunotherapy: a beneficial liaison? RR Weichselbaum, H Liang, L Deng, YX Fu Nature reviews Clinical oncology 14 (6), 365	2017
Microbiota: a key orchestrator of cancer therapy S Roy, G Trinchieri Nature Reviews Cancer 17 (5), 271	2017
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? C Tang, X Wang, H Soh, S Seyedin, MA Cortez, S Krishnan, E Massarelli, ... Cancer immunology research 2 (9), 831-838	2014

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.